


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound represented by formula (1):

Formula 1



wherein

R<sup>1</sup>, R<sup>2</sup> and R<sup>5</sup> are each independently selected from a hydrogen atom, a halogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl group which may be substituted with one or more halogen atoms and a C<sub>1</sub>-C<sub>6</sub> alkoxy group which may be substituted with one or more halogen atoms;

R<sup>3</sup> and R<sup>4</sup> are each independently selected from a hydrogen atom, a halogen atom, -NR<sub>f</sub>R<sub>g</sub>, -CONR<sub>f</sub>R<sub>g</sub>, -CH=NOR<sub>e</sub>, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a C<sub>1</sub>-C<sub>6</sub> alkyl group and -T-(CH<sub>2</sub>)<sub>k</sub>-V, wherein the alkyl group and the alkoxy group may be substituted with one or more

substituents selected from a hydroxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a halogen atom and -NR<sub>f</sub>R<sub>g</sub>;  
wherein

Re is selected from a hydrogen atom and C<sub>1</sub>-C<sub>6</sub> alkyl, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a halogen atom and -NR<sub>h</sub>R<sub>i</sub>,

R<sub>f</sub> and R<sub>g</sub> are each independently selected from a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl group and C<sub>1</sub>-C<sub>6</sub> alkylcarbonyl group, wherein the alkyl group and the alkylcarbonyl group may be substituted with one to three substituents selected from a hydroxyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy group, a halogen atom and -NR<sub>h</sub>R<sub>i</sub>,

R<sub>h</sub> and R<sub>i</sub> are each independently selected from a hydrogen atom and C<sub>1</sub>-C<sub>6</sub> alkyl group, wherein the alkyl group may be substituted with one to three substituents selected from a hydroxyl group, a halogen atom and a C<sub>1</sub>-C<sub>6</sub> alkoxy group, or

R<sub>f</sub> and R<sub>g</sub>, and R<sub>h</sub> and R<sub>i</sub> together with a nitrogen atom to which they are attached may form a 4- to

7-heterocycle, wherein the heterocycle may be substituted with a C<sub>1</sub>-C<sub>6</sub> alkyl group,

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more Y<sup>3</sup>, -NRaRb, -CONRaRb, -OC(=O)NRaRb, -SO<sub>2</sub>NRaRb, -N(-Ra)C(=O)NRa'Rb', -N(-Ra)C(=O)ORd, -C(=O)ORd, -S(=O)<sub>m</sub>-Rd, -O-Rd, -OC(=O)Rc, -N(-Ra)C(=O)Rc, -N(Ra)SO<sub>2</sub>Rc, -C(=NRa)NRa'Rb', -C(=NORa)Rc or -C(=O)Rc;

R<sup>6</sup> and R<sup>7</sup> are each independently selected from a hydrogen atom and a halogen atom;

Z<sup>1</sup> and Z<sup>2</sup> are each independently selected from a hydrogen atom, a hydroxyl group and -O(CHR<sup>11</sup>)OC(=O)R<sup>12</sup>;

wherein


R<sup>11</sup> is a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl group;

R<sup>12</sup> is a pyrrolidinyl group, a piperidinyl group, a morpholinyl group, a piperazinyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkyl group, a mono- or di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkylamino group

or a mono- or di(C<sub>1</sub>-C<sub>6</sub> alkyl)-amino C<sub>1</sub>-C<sub>6</sub>  
alkylamino group;

Q is a group of

Formula 2



wherein

Y<sup>1</sup> is selected from the group consisting of a  
hydrogen atom, a halogen atom, a C<sub>1</sub>-C<sub>6</sub> alkyl  
group, and a C<sub>2</sub>-C<sub>6</sub> alkenyl group, a C<sub>1</sub>-C<sub>6</sub> alkoxy  
group, a mono- or dihydroxy C<sub>1</sub>-C<sub>6</sub> alkyl group, a  
C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkoxy group, an amino C<sub>1</sub>-C<sub>6</sub>  
alkoxy group, a (C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkoxy  
group, a di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkoxy group, a  
C<sub>1</sub>-C<sub>6</sub> alkoxy C<sub>1</sub>-C<sub>6</sub> alkyl group, an amino C<sub>1</sub>-C<sub>6</sub> alkyl  
group, a (C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkyl group, a  
di(C<sub>1</sub>-C<sub>6</sub> alkyl)amino C<sub>1</sub>-C<sub>6</sub> alkyl group, an amino  
group, a (C<sub>1</sub>-C<sub>6</sub> alkyl)amino group and a di(C<sub>1</sub>-C<sub>6</sub>  
alkyl)amino group;

Wherein

Q is optionally substituted by at least one  
substituents W, where W is ~~a halogen atom, a nitro  
group, a cyano group, a hydroxyl group, -NRaRb,  
-N=C(-Rc)NRaRb, -CONRaRb, -OC(=O)NRaRb,  
SO<sub>2</sub>NRaRb, -N(-Ra)C(=O)NRa'Rb', or -N(-  
Ra)C(=O)ORD, -N[C(=O)ORD][C(=O)ORD'],  
C(=O)ORD, -S(=O)<sub>m</sub>-Rd, -O-Rd, -OC(=O)Re,  
-N(-Ra)C(=O)Re, -N[C(=O)Re][C(=O)Re'], N(-  
Ra)SO<sub>2</sub>Re, -N(SO<sub>2</sub>Re)(SO<sub>2</sub>Re'), -C(=NORD)NRa'Rb',  
C(=NRa)NRa'Rb', -C(=NORa)Re, -C(=O)Re, a C<sub>1</sub>-C<sub>6</sub>  
alkyl group which may be substituted with one or  
more Y<sup>3</sup>, a C<sub>2</sub>-C<sub>2</sub> alkenyl group which may be  
substituted with one or more Y<sup>3</sup>, a C<sub>2</sub>-C<sub>2</sub> alkynyl  
group which may be substituted with one or more  
Y<sup>3</sup>, an aryl group which may be substituted with  
one or more Y<sup>3</sup> or a heteroaryl group which may be  
substituted with one or more Y<sup>3</sup>;~~

Ra, Ra', Rb, Rb', Rc, Re', and Rd and Rd' are each  
independently selected from the group consisting  
of a hydrogen atom, a C<sub>1</sub>-C<sub>10</sub> alkyl group, a C<sub>3</sub>-C<sub>8</sub>  
cycloalkyl group, a C<sub>2</sub>-C<sub>8</sub> alkenyl group, a C<sub>2</sub>-C<sub>8</sub>

alkynyl group,  $-\text{[(C}_1\text{-C}_6\text{ alkylene)-O]}_n\text{-(C}_1\text{-C}_3\text{ alkyl)}$ , a tetrahydropyranyl group, a tetrahydrofuranyl group, an aryl group, a heteroaryl group, and a nitrogen-containing heterocyclyl group (wherein the nitrogen atom on the heterocyclyl group may be substituted with a  $\text{C}_1\text{-C}_3$  alkyl group); or

Ra and Rb, Ra' and Rb', Ra and Rd, Ra and Ra', Ra and Rc, ~~Re and Re'~~, and Rd and Ra' may form a saturated or unsaturated 5- to 6-membered heterocycle by ring-closing at the bonding position of each of these two groups and the heterocycle may be substituted with a  $\text{C}_1\text{-C}_6$  alkyl group;

Ra, Ra', Rb, Rb', Rc, ~~Re'~~, and Rd and ~~Rd'~~ each may be substituted with one to three same or different substituents selected from  $\text{Y}^3$ ;

m is an integer selected from 0 to 2;

n is an integer selected from 1 to 4;

$\text{Y}^3$  is a halogen atom,  $-\text{NRxRy}$ ,  $-\text{C(=O)ORz}$ ,  $-\text{C(=O)Rz}$ ,  $-\text{ORz}$ ,  $-\text{C(=O)NRxRy}$ ,  $-\text{OC(=O)NRxRY}$ ,  $-\text{SO}_2\text{NRxRy}$ ,  $-\text{N(-Rx)C(=O)NRx'Ry'}$ ,  $-\text{N(-Rx)C(=O)ORz}$ ,  $-\text{S-Rz}$ ,

-SO-Rz, -SO<sub>2</sub>-Rz, -OC(=O)Rz, -N(Rx)C(=O)Rz,  
-C(=NORz)NRx'Ry', -C(=NRx)NRx'Ry', -C(=NORx)Rz,  
-[O-(C<sub>1</sub>-C<sub>6</sub> alkylene)]<sub>n</sub>-O(C<sub>1</sub>-C<sub>3</sub> alkyl), -N(-Rx)-(C<sub>1</sub>-  
C<sub>6</sub> alkylene)-O(C<sub>1</sub>-C<sub>3</sub> alkyl), -C(=O)Rz, a C<sub>1</sub>-C<sub>6</sub> alkyl  
group, a C<sub>2</sub>-C<sub>8</sub> alkenyl group, a C<sub>2</sub>-C<sub>8</sub> alkynyl  
group, an aryl group or a heteroaryl group;


Rx, Rx', Ry, Ry' and Rz are each independently  
selected from a hydrogen atom and a C<sub>1</sub>-C<sub>4</sub> alkyl  
group;

Rx and Ry, Rx and Rx', Rx and Rz, and Rz and Rx'  
may form a saturated or unsaturated 5-to 6-  
membered heterocycle by ring-closing at the  
bonding position of each of these two groups;  
a pharmaceutically acceptable salt thereof ~~or a prodrug~~  
thereof.

2. (Currently Amended) The compound of claim  
1, or a pharmaceutically acceptable salt thereof ~~or a~~  
~~prodrug thereof~~, wherein R<sup>2</sup> is selected from a halogen  
atom, a trifluoromethyl group and a trifluoromethoxy  
group.

3. (Currently Amended) The compound of claim 2, a pharmaceutically acceptable salt thereof ~~or a prodrug thereof~~, wherein Q is a group of the formula selected from

Formula 3



which may be substituted with one to three same or different substituents W.

Claims 4-5. (Cancelled)

6. (Currently Amended) The compound of claim 1, or a pharmaceutically acceptable salt thereof ~~or a prodrug thereof~~,  
wherein

R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each independently selected from a hydrogen atom, a chlorine atom, a fluorine atom, a bromine atom and a trifluoromethyl



group;

$R^6$  and  $R^7$  are hydrogen atoms; and

$Z^1$  and  $Z^2$  are each independently selected from a hydrogen atom, and a hydroxyl group.

7. (Currently Amended) The compound of claim 1, ~~or a pharmaceutically acceptable salt thereof or a prodrug thereof,~~

wherein

$R^3$  and  $R^4$  are each independently selected from a hydrogen atom, a halogen atom, a  $C_1$ - $C_6$  alkyl group which may be substituted with one or more hydroxyl groups or halogen atoms, a  $C_1$ - $C_6$  alkoxy group which may be substituted with one or more halogen atoms, and  $-T-(CH_2)_k-V$ ;

T is an oxygen atom or a single bond; k is an integer selected from 0 to 4;

V is a 5- to 6-membered heterocyclyl group which may be substituted with one or more substituents selected from a hydroxy group, an amino group,  $C_1$ - $C_6$  alkyl group,  $C_1$ - $C_6$  alkoxy group and  $C_1$ - $C_6$  alkylcarbonyl group.

8. (Currently Amended) A compound~~7~~ or a pharmaceutically acceptable salt thereof ~~or a prodrug thereof~~ of claim 1 which has Raf inhibiting effect and angiogenesis inhibiting effect and is used for treating cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes.

9. (Currently Amended) A pharmaceutical composition comprising a compound~~7~~ or a pharmaceutically acceptable salt thereof ~~or a prodrug thereof~~ of claim 1 as an active ingredient.

10. (Currently Amended) An Raf inhibitor or an angiogenesis inhibitor comprising a compound~~7~~ or a pharmaceutically acceptable salt thereof ~~or a prodrug thereof~~ of claim 1 as an active ingredient.

11. (Currently Amended) A ~~preventive or~~ therapeutic agent for a disease selected from cancer, psoriasis, atherosclerosis, chronic rheumatoid arthritis and diabetes which comprises a compound~~7~~ or a pharmaceutically acceptable salt thereof ~~or a prodrug thereof~~ of claim 1 as an active ingredient.

Claims 12-13. (Cancelled)